Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine

MHRA has advised that any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine; and a second dose should not be given to anyone who has experienced anaphylaxis following administration of the first dose of this vaccine

SPS commentary:

Updated guidance has been issued to COVID-19 vaccination centres about the management of anaphylaxis, following two reports of anaphylaxis and one report of a possible allergic reaction following immunisation. An Expert Group of the Commission on Human Medicines (CHM) has been convened to robustly review these reports to consider any possible mitigation on the rare risk of anaphylaxis. This guidance confirms the precautionary advice to healthcare professionals issued yesterday.


Medicines and Healthcare products Regulatory Agency